Clinical trial
Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With…
NCT02500381 · Sarepta Therapeutics, Inc., Industry · Completed
Key facts
| NCT number | NCT02500381 |
|---|---|
| Title | Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD) |
| Official title | A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy |
| Acronym | ESSENCE |
| Lead sponsor | Sarepta Therapeutics, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Duchenne Muscular Dystrophy |
| Intervention type | Drug |
| Interventions | SRP-4045, SRP-4053, Placebo |
| Enrollment | 228 |
| Start date | Sep 28, 2016 |
| Primary completion | Nov 12, 2024 |
| Completion | Oct 16, 2025 |
| First posted | Jul 16, 2015 |
| Last update posted | Nov 18, 2025 |
| Countries | Argentina, Australia, Belgium, Bulgaria, Canada, Czechia, Denmark, France, Germany, Greece, Hungary, India and 12 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: